Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of the drug elranatamab, both alone and in combination with daratumumab, for patients with relapsed or refractory multiple myeloma. The study aims to determine if elranatamab can offer greater benefits compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone. This trial is significant as it explores new treatment avenues for patients who have previously undergone other therapies.
The interventions being tested include elranatamab, a BCMA-CD3 bispecific antibody, and daratumumab, an anti-CD38 monoclonal antibody. These drugs are administered subcutaneously, with pomalidomide and dexamethasone given orally in the comparator group.
The study follows a randomized, open-label design with a factorial intervention model and no masking. Its primary purpose is treatment-focused, aiming to assess the safety and activity of the interventions.
The trial began on October 4, 2021, and is currently recruiting participants. The last update was submitted on June 23, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential market entry.
This clinical update could influence Pfizer’s stock performance positively if the results demonstrate significant efficacy and safety, potentially enhancing investor confidence. The outcome may also impact competitors in the multiple myeloma treatment space, prompting strategic adjustments.
The study is ongoing, with further details available on the ClinicalTrials portal.